To evaluate the efficacy and safety of trilaciclib combined with standard treatment project as a neoadjuvant treatment for triple negative breast cancer
Newly treated patients aged ≥ 18 years;
ECOG score 0-1;
Histologically confirmed invasive breast cancer
Tumor staging: cT2-4, cNany, cM0 or cT1, cN1-3, cM0;
Previously received anti-tumor treatment for any malignant tumor;
Subjects who are unable to accept or tolerate preoperative chemotherapy due to various reasons;
The patient has undergone major surgical procedures unrelated to breast cancer within 4 weeks before enrollment, or has not fully recovered from such surgical procedures;
A confirmed history of heart failure or systolic dysfunction (LVEF<50%);